ravulizumab (Ultomiris)

Indications

• paroxysmal nocturnal hemoglobinuria

Dosage

• every 8 weeks

* immunization with meningococcal vaccines >= 2 weeks prior to 1st dose of ravulizumab

Adverse effects

• headache
• upper respiratory infection

Boxed Warning

• risk of life-threatening meningococcal infections & sepsis
  • vaccination reduces, but does not eliminate, risk of meningococcal infection

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• long-acting complement inhibitor that prevents hemolysis
• binds complement C5 & inhibits terminal complement cascade

More general terms

• hematologic agent
• pharmaceutical monoclonal antibody